1. Onset of azoospermia in man treated with ipilimumab/nivolumab for BRAF negative metastatic melanoma
- Author
-
Amin S. Herati, Iryna V. Samarska, Matthew J. Rabinowitz, Taylor P. Kohn, Vanessa N. Peña, and Andres Matoso
- Subjects
Male ,Infertility ,Oncology ,endocrine system ,medicine.medical_specialty ,immune Checkpoint inhibitor therapy ,ICI, immune checkpoint inhibitor ,Urology ,030232 urology & nephrology ,Ipilimumab ,lcsh:RC870-923 ,BRAF ,Male infertility ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,reproductive and urinary physiology ,Microdissection ,Azoospermia ,urogenital system ,business.industry ,mTESE, microscopic testicular sperm extraction ,SA, semen analysis ,lcsh:Diseases of the genitourinary system. Urology ,medicine.disease ,Sperm ,Testicular sperm extraction ,Andrology and Fertility ,030220 oncology & carcinogenesis ,CTLA-4, Cytotoxic T-Lymphocyte antigen-4 ,Immunotherapy ,Nivolumab ,business ,medicine.drug - Abstract
Azoospermia is classified as the complete absence of sperm in ejaculate and accounts for 10–15% of male infertility. Many anticancer drugs are known to cause defects in spermatogenesis, but the effects of immune checkpoint inhibitor cancer therapy on spermatogenesis remains largely unknown. Presented here is a normozoospermic man (60 million sperm/cc of ejaculate) who received a trial combination treatment of Ipilimumab/Nivolumab to treat BRAF negative, stage IV metastatic melanoma. Two years after the treatment, the patient presented as completely azoospermic. The patient subsequently underwent microdissection testicular sperm extraction, during which no sperm was retrieved, and sertoli-only pathology was elucidated., Highlights • Normozoospermic man became azoospermic after Ipilimumab/Nivolumab treatment. • Testicular biopsy revealed sertoli-only pathology. • Effect of Ipilimumab/Nivolumab on spermatogenesis remains largely unknown.
- Published
- 2021
- Full Text
- View/download PDF